Heyholder
‹ Activism Filings

IL DONG PHARMACEUTICAL CO., LTD. Q3 profit from main business KRW 7.1 billion on KRW 151.0 billion sales; net loss

IL DONG PHARMACEUTICAL CO., LTD.· Periodic Report

AI summary · Not investment advice

Iljin...

Operating profit · 3 months

KRW 7.1 billion

Key facts

Revenue (3 months)
KRW 151.0 billion
Net income (3 months)
KRW -5.2 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 145.5 billion
Revenue (year to date)
KRW 440.8 billion
Operating profit (prior-year 3 months)
KRW 6.8 billion
Operating profit (year to date)
KRW 18.4 billion
Net income (prior-year 3 months)
KRW 21.5 billion
Net income (year to date)
KRW 7.2 billion

Commentary

AI commentary · Not investment advice

What happened

Ildong Pharmaceutical reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 150.96 billion. That is 3.8% above the same 3 months a year earlier (KRW 145.46 billion) and 2.1% above the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was KRW 7.14 billion. That is 5.7% above the same period a year earlier (KRW 6.76 billion). It is 260.8% above the previous quarter.

What changes for shareholders

Net income (final profit after taxes and all other costs) for the 3 months was a loss of KRW 5.23 billion. A year earlier, the same 3 months showed net income of KRW 21.49 billion. The company swung to a loss from the previous quarter.

For the year to date, sales were KRW 440.82 billion. Operating profit was KRW 18.35 billion. Net income was KRW 7.25 billion.

Comments

No comments yet

Comments from shareholders will appear here.